Veracyte Announces First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Veracyte, Inc (VCYT) PT Lowered to $26 at Needham & Company
May 4, 2022 6:51 AM EDTNeedham & Company analyst Mike Matson lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $26.00 (from $31.00) while maintaining a Buy rating following earnings.
The analyst commented, "VCYT's 1Q22 revenue and EPS beat consensus. Organic revenue growth (excluding estimated revenue from Decipher and... More
Veracyte (VCYT) Tops Q1 EPS by 4c
May 3, 2022 4:40 PM EDTVeracyte (NASDAQ: VCYT) reported Q1 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $67.8 million versus the consensus estimate of $62.32 million.
GUIDANCE:
Veracyte sees FY2022 revenue of $265-275 million, versus the consensus of $270... More
